Yuan Dong Bio announced that on July 16, 2026, it received the Drug Registration Certificate for Remimazolam Besylate for Injection approved and issued by the National Medical Products Administration, with a specification of 25 mg, approved under chemical drug category 4, making it the first domestic company to receive approval for this generic drug. The drug is a Class II psychotropic substance, indicated for sedation and anesthesia in non-tracheal intubation procedures or operations, as well as for the induction and maintenance of general anesthesia.
Chengdu Easton Biopharmaceuticals Co LtdReceived first domestic generic approval for Remimazolam Besylate for Injection, a regulatory milestone.